

Heli Harvala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1990352/publications.pdf>

Version: 2024-02-01

68
papers

2,644
citations

159525

30
h-index

206029

48
g-index

74
all docs

74
docs citations

74
times ranked

4209
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Convalescent Plasma on Organ Supportâ€“Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	3.8	169
2	Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. Journal of Clinical Virology, 2018, 101, 11-17.	1.6	161
3	Parechoviruses in children: understanding a new infection. Current Opinion in Infectious Diseases, 2010, 23, 224-230.	1.3	128
4	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 2020, 5, 181.	0.9	122
5	Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications, 2020, 11, 6385.	5.8	103
6	Comparison of human parechovirus and enterovirus detection frequencies in cerebrospinal fluid samples collected over a 5â€“year period in edinburgh: HPeV type 3 identified as the most common picornavirus type. Journal of Medical Virology, 2011, 83, 889-896.	2.5	100
7	High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. Journal of Medical Virology, 2013, 85, 893-898.	2.5	94
8	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 2020, 5, 181.	0.9	81
9	Molecular epidemiology and evolution of coxsackievirus A9. Microbiology (United Kingdom), 2000, 81, 1361-1372.	0.7	79
10	Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infectious Diseases, The, 2020, 20, 350-361.	4.6	76
11	Convalescent plasma therapy for the treatment of patients with COVIDâ€“19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfusion Medicine, 2021, 31, 167-175.	0.5	71
12	Detection and Genetic Characterization of Enteroviruses Circulating among Wild Populations of Chimpanzees in Cameroon: Relationship with Human and Simian Enteroviruses. Journal of Virology, 2011, 85, 4480-4486.	1.5	65
13	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance, 2020, 25, .	3.9	64
14	Genetics, Recombination and Clinical Features of Human Rhinovirus Species C (HRV-C) Infections; Interactions of HRV-C with Other Respiratory Viruses. PLoS ONE, 2009, 4, e8518.	1.1	62
15	Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. Journal of General Virology, 2015, 96, 1067-1079.	1.3	55
16	Variability and pathogenicity of hepatitis E virus genotype 3 variants. Journal of General Virology, 2015, 96, 3255-3264.	1.3	54
17	Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Eurosurveillance, 2020, 25, .	3.9	53
18	Distinct systemic and central nervous system disease patterns in enterovirus and parechovirus infected children. Journal of Infection, 2014, 69, 69-74.	1.7	50

#	ARTICLE	IF	CITATIONS
19	Environmental Surveillance Reveals Complex Enterovirus Circulation Patterns in Human Populations. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy250.	0.4	47
20	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	1.3	46
21	Development and Assay of RNA Transcripts of Enterovirus Species A to D, Rhinovirus Species A to C, and Human Parechovirus: Assessment of Assay Sensitivity and Specificity of Real-Time Screening and Typing Methods. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2910-2917.	1.8	44
22	Rapid Simultaneous Detection of Enterovirus and Parechovirus RNAs in Clinical Samples by One-Step Real-Time Reverse Transcription-PCR Assay. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2620-2624.	1.8	43
23	Emergence of a novel subclade of influenza A(H3N2) virus in London, December 2016 to January 2017. <i>Eurosurveillance</i> , 2017, 22, .	3.9	42
24	Recommendations for the introduction of metagenomic high-throughput sequencing in clinical virology, part I: Wet lab procedure. <i>Journal of Clinical Virology</i> , 2021, 134, 104691.	1.6	42
25	The need for treatment against human parechoviruses: how, why and when?. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1417-1429.	2.0	38
26	The importance of enterovirus surveillance in a post-polio world. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e35-e40.	4.6	38
27	Epidemiology and clinical characteristics of parainfluenza virus 3 outbreak in a Haemato-oncology unit. <i>Journal of Infection</i> , 2012, 65, 246-254.	1.7	35
28	Increase in Enterovirus D68 Infections in Young Children, United Kingdom, 2006–2016. <i>Emerging Infectious Diseases</i> , 2019, 25, 1200-1203.	2.0	35
29	Strategies to improve detection and management of human parechovirus infection in young infants. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e51-e58.	4.6	35
30	Co-circulation of enteroviruses between apes and humans. <i>Journal of General Virology</i> , 2014, 95, 403-407.	1.3	33
31	Surveillance and laboratory detection for non-polio enteroviruses in the European Union/European Economic Area, 2016. <i>Eurosurveillance</i> , 2017, 22, .	3.9	33
32	Mapping of tissue tropism determinants in coxsackievirus genomes. <i>Journal of General Virology</i> , 2002, 83, 1697-1706.	1.3	32
33	Tissue tropism of recombinant coxsackieviruses in an adult mouse model. <i>Journal of General Virology</i> , 2005, 86, 1897-1907.	1.3	31
34	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. <i>Eurosurveillance</i> , 2021, 26, .	3.9	31
35	Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction. <i>Transfusion</i> , 2021, 61, 2837-2843.	0.8	29
36	Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	28

#	ARTICLE	IF	CITATIONS
37	Understanding the outcomes of COVID-19 – does the current model of an acute respiratory infection really fit?. <i>Journal of General Virology</i> , 2021, 102, .	1.3	25
38	Acute viral hepatitis – Should the current screening strategy be modified?. <i>Journal of Clinical Virology</i> , 2014, 59, 184-187.	1.6	24
39	High Seroprevalence of Enterovirus Infections in Apes and Old World Monkeys. <i>Emerging Infectious Diseases</i> , 2012, 18, 283-286.	2.0	20
40	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	1.9	20
41	Hepatitis B infections among blood donors in <scp>England</scp> between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety?. <i>Transfusion</i> , 2021, 61, 2402-2413.	0.8	19
42	Role of Sequencing the Measles Virus Hemagglutinin Gene and Hypervariable Region in the Measles Outbreak Investigations in Sweden During 2013–2014. <i>Journal of Infectious Diseases</i> , 2016, 213, 592-599.	1.9	18
43	Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, Europe. <i>Emerging Infectious Diseases</i> , 2021, 27, 1616-1626.	2.0	18
44	European Non-Polio Enterovirus Network: Introduction of Hospital-Based Surveillance Network to Understand the True Disease Burden of Non-Polio Enterovirus and Parechovirus Infections in Europe. <i>Microorganisms</i> , 2021, 9, 1827.	1.6	18
45	Case report: Eastern equine encephalitis virus imported to the UK. <i>Journal of Medical Virology</i> , 2009, 81, 305-308.	2.5	17
46	Convalescent plasma therapy for persistent hepatitis E virus infection. <i>Journal of Hepatology</i> , 2019, 71, 434-438.	1.8	17
47	Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. <i>Vox Sanguinis</i> , 2021, 116, 493-496.	0.7	17
48	Cardiomyocyte Apoptosis after Antiviral WIN 54954 Treatment in Murine Coxsackievirus B3 Myocarditis. <i>Scandinavian Cardiovascular Journal</i> , 2002, 36, 187-192.	0.4	16
49	Epidemiology of <i>Campylobacter jejuni</i> infections in Sweden, November 2011–October 2012: is the severity of infection associated with <i>C. jejuni</i> sequence type?. <i>Infection Ecology and Epidemiology</i> , 2016, 6, 31079.	0.5	16
50	Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials. <i>Critical Care</i> , 2020, 24, 449.	2.5	16
51	Pathogenesis of coxsackievirus A9 in mice: role of the viral arginine-glycine-aspartic acid motif. <i>Journal of General Virology</i> , 2003, 84, 2375-2379.	1.3	15
52	High Rates of Infection with Novel Enterovirus Variants in Wild Populations of Mandrills and Other Old World Monkey Species. <i>Journal of Virology</i> , 2014, 88, 5967-5976.	1.5	15
53	Seroprevalence and Virologic Surveillance of Enterovirus 71 and Coxsackievirus A6, United Kingdom, 2006–2017. <i>Emerging Infectious Diseases</i> , 2021, 27, 2261-2268.	2.0	15
54	Pathogenicity of individual rhinovirus species during exacerbations of cystic fibrosis. <i>European Respiratory Journal</i> , 2015, 45, 1748-1751.	3.1	14

#	ARTICLE	IF	CITATIONS
55	Viral meningitis: epidemiology and diagnosis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1211-1212.	4.6	11
56	Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. <i>Sexually Transmitted Infections</i> , 2022, 98, 132-135.	0.8	10
57	Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization. <i>Transfusion</i> , 2022, 62, 1347-1354.	0.8	9
58	Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2022, 225, 971-976.	1.9	5
59	Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres. <i>Transfusion Medicine</i> , 2022, 32, 327-337.	0.5	5
60	Detection frequencies and viral load distribution of parvovirus B19 DNA in blood and plasma donations in England. <i>Transfusion Medicine</i> , 2022, 32, 402-409.	0.5	4
61	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
62	Lessons learnt from syphilis-infected blood donors: a timely reminder of missed opportunities. <i>Sexually Transmitted Infections</i> , 2021, , sextrans-2021-055034.	0.8	2
63	Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's COVID-19 Public Health Response. <i>Microbiology Spectrum</i> , 2022, 10, e0228921.	1.2	2
64	Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020. <i>Journal of Global Health</i> , 2021, 11, 05014.	1.2	1
65	Evaluation of the national laboratory-based surveillance system for respiratory syncytial virus in Sweden, 2015-2016. <i>Journal of Clinical Virology</i> , 2018, 104, 11-15.	1.6	0
66	Bitten in the Hampshires. , 2019, , 145-148.		0
67	Comparison of SARS-CoV-2 neutralizing antibody testing of convalescent plasma donations in the Netherlands and England: A pilot study. <i>Health Science Reports</i> , 2021, 4, e439.	0.6	0
68	Blood donor notification of variant Creutzfeldt-Jakob disease risk: Lessons in communicating donor deferral and risk. <i>Transfusion Medicine</i> , 0, , .	0.5	0